Tibetan capillary capsule and preparation method thereof

By using the combination of the Cantanese extract of alcohol extract and specific auxiliary materials, the problem of poor fluidity of Cantanese capsules is solved, and the stability and quality improvement is achieved, and it is suitable for clinical and industrial production.

CN118924695AActive Publication Date: 2024-11-12NORTHWEST INST OF PLATEAU BIOLOGY CHINESE ACAD OF SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411008462.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

The viscosity and poor fluidity of the Tibetan Artemisia extract affect the stability of the capsule and the quality of the drug, making it difficult to promote and apply it in clinical practice.

Method used

Alcohol extract is used as the extract of Candida extract, and through the combination of auxiliary materials with specific ratios, including mannitol, magnesium stearate and colloidal silica as fillers and glidants, the fluidity and density of the capsules are increased, and the filling is filled. In the capsule shell.

Benefits of technology

The obtained Zangyinchen capsule has a small angle of rest, good fluidity, large bulk density and tap density, the quality meets the requirements of the pharmacopoeia, is low in cost, and is suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924695A_ABST
    Figure CN118924695A_ABST
Patent Text Reader

Abstract

The Tibetan capillary artemisia capsule content is prepared from the following raw and auxiliary materials in percentage by weight: 55 to 59 percent of filling agent, 3 to 6 percent of flow aid and the balance of Tibetan capillary artemisia extract, the Tibetan capillaris extract is an alcohol extract of Tibetan capillaris. The Tibetan capillary artemisia granules not only meet the requirements of pharmacopeia in quality, but also are low in cost and suitable for actual industrial mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and particularly relates to a Tibetan Artemisia Capsule. Background Art

[0002] Tibetan Artemisia capillaris is the dried whole herb of Swertia mussotii Franch., a plant of the Gentianaceae family. It mainly contains flavonoids, xanthones, iridoids and their glycosides, triterpenes and alkaloids, and has the effects of clearing away heat and detoxifying, clearing the liver and promoting bile secretion, removing dampness and relieving jaundice, and strengthening the stomach. It has an important position in traditional Chinese medicine and Tibetan medicine, and is used to treat icteric hepatitis, cirrhosis, ascites, cholecystitis, biliary syndrome, bile duct reflux gastritis, indigestion, acute bacillary dysentery, acute icteric hepatitis, acute conjunctivitis, acute pharyngitis and burns.

[0003] Because the decoction of Tibetan Artemisia Capillaris is extremely bitter and difficult for patients to accept, it is currently made into modern preparations such as granules and capsules for clinical use. However, due to the high viscosity and poor fluidity of the Tibetan Artemisia Capillaris extract, the selection of excipients will affect the stability of the capsule and the quality of the drug, which is not conducive to clinical promotion and application. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a Tibetan Artemisia Capsule, which is prepared from the following raw materials and auxiliary materials in the following weight percentages:

[0005] Filler 55%-59%, flow aid 3%-6%, the rest is Tibetan Artemisia capillaris extract;

[0006] The Tibetan Artemisia Capillaris extract is an alcohol extract of Tibetan Artemisia Capillaris.

[0007] Furthermore, it is prepared from the following raw materials in percentage by weight:

[0008] Filler 58.2%, flow aid 3%, Tibetan Artemisia Capillaris extract 38.8%.

[0009] Furthermore, the filler is mannitol.

[0010] Furthermore, the glidant is magnesium stearate and / or silicon dioxide.

[0011] Furthermore, the glidant is magnesium stearate and silicon dioxide in a mass ratio of 1:2-5.

[0012] Furthermore, the glidant is magnesium stearate and silicon dioxide in a mass ratio of 1:2.

[0013] Furthermore, the silicon dioxide is colloidal silicon dioxide.

[0014] Furthermore, the Tibetan Artemisia Capillaris extract is an extract obtained by reflux extraction of Tibetan Artemisia Capillaris with 75% ethanol, and removing ethanol and medicinal residues from the extract.

[0015] The present invention also provides a Tibetan Artemisia Capsule, which is a capsule prepared by filling the aforementioned contents into a capsule shell.

[0016] The present invention also provides a method for preparing the aforementioned Tibetan Artemisia Capsule, which comprises the following steps:

[0017] Weigh the raw and auxiliary materials according to the above ratio, mix them evenly, and fill them into capsule shells to obtain the product.

[0018] The capillaris capsule of the present invention is prepared by mixing specific auxiliary materials in different amounts and has a small angle of repose, good fluidity, large bulk density and tap density. The capsule is filled in a capsule shell, and the quality of the obtained capsule meets the requirements of the pharmacopoeia, and the cost is low, so the capsule is suitable for actual large-scale industrial production.

[0019] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0020] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 HPLC chromatograms of the control (A), test (B), and negative control (C) solutions; 1. swertiamain 2. gentiopicrin 3. swertiain DETAILED DESCRIPTION

[0022] Example 1 Preparation of Tibetan Artemisia Capsules

[0023] formula:

[0024] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 38.8% Fillers Mannitol 58.2% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 2%

[0025] Preparation method:

[0026] 1) Preparation of Tibetan Artemisia Capillaris extract: Take Tibetan Artemisia Capillaris, crush it, add 6 times the amount of 75% ethanol and reflux it for 2 hours, extract it 3 times in total, remove the ethanol and the drug residue from the extract to obtain the extract;

[0027] 2) Weigh the raw materials and auxiliary materials according to the proportion, mix well, and fill them into capsule shells to obtain the product.

[0028] Example 2 Preparation of Tibetan Artemisia Capsules

[0029] formula:

[0030] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 39% Fillers Mannitol 58% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 2%

[0031] Preparation method: Same as Example 1

[0032] Example 3 Preparation of Tibetan Artemisia Capsules

[0033] formula:

[0034] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 38% Fillers Mannitol 59% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 2%

[0035] Preparation method: Same as Example 1

[0036] Example 4 Preparation of Tibetan Artemisia Capsules

[0037] formula:

[0038] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 39% Fillers Mannitol 55% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 5%

[0039] Preparation method: Same as Example 1

[0040] Example 5 Preparation of Tibetan Artemisia Capsules

[0041] formula:

[0042] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 40% Fillers Mannitol 56% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 3%

[0043] Preparation method: Same as Example 1

[0044] The beneficial effects of the present invention are specifically described below through test examples.

[0045] Experimental Example 1 Study on the Excipient Formula of Tibetan Artemisia Capsules

[0046] 1. Prescription optimization

[0047] Based on the preliminary tests, it was determined that the API had good water solubility but poor fluidity. Therefore, mannitol and microcrystalline cellulose were initially selected as fillers, and magnesium stearate and colloidal silicon dioxide were mixed as flow aids and then directly filled, which had a simple process and a high drug loading capacity.

[0048] 1.1 Reagents and Equipment

[0049] Table 1 Experimental drugs and reagents

[0050]

[0051] Table 2 Experimental instruments and equipment

[0052]

[0053] 1.2 Experimental methods

[0054] Sample preparation: weigh the raw material Tibetan Artemisia capillaris extract and the auxiliary fillers and flow aids, i.e. mannitol, colloidal silicon dioxide and magnesium stearate, according to the prescription design, mix for 30 minutes and fill. Take samples for performance testing. The Tibetan Artemisia capillaris extract is prepared as follows: Tibetan Artemisia capillaris is crushed, refluxed and extracted for 2 hours with 6 times the amount of 75% ethanol, extracted 3 times in total, and the extract is free of ethanol and impurities to obtain the extract.

[0055] 1.2.1 Liquidity

[0056] The sample is passed through a glass funnel and flows vertically onto a glass plate. The tail end of the funnel is 3 cm away from the glass plate. The powder flows down to form a cone on the glass plate. The angle between the cone surface and the horizontal plane is measured. This is the angle of repose of the sample.

[0057] 1.2.2 Bulk density and tap density

[0058] 1.2.2.1 Bulk density

[0059] According to the "0993 Bulk Density and Tap Density Determination Method" in the "Chinese Pharmacopoeia" (2020 Edition), it is used to determine the filling density of drug or excipient powders in a loose state. The loose state refers to the state formed when a powder sample is poured into a container without the action of compression force. The bulk density can be determined by measuring the volume of a certain mass of powder sample in a measuring cylinder after sieving (the first method), take about 100g of the powder sample to be tested (if necessary, it should be passed through a sieve with a pore size of 1.0mm to fully disperse the lumps formed during storage.), accurately weigh, slowly pour into a glass graduated cylinder, carefully scrape the top, avoid compacting the powder, and record the apparent volume V1 at the closest scale line. Take 3 samples from the same batch, measure them in parallel, record the readings, and take the average value as the measurement result.

[0060] The bulk density was calculated according to the formula: bulk density ρa = M / V1, where ρa is the fixed mass method bulk density (g / mL), M is the mass of the powder sample (g), and V1 is the volume of the drug powder (mL).

[0061] 1.2.2.2 Tap density

[0062] According to the "0993 Bulk Density and Tap Density Determination Method" in the "Chinese Pharmacopoeia" (2020 Edition), the tap density is determined by measuring the tapped volume of a fixed mass sample. The measuring device includes a graduated cylinder and a tapping device (the tapping frequency is 250 times ± 15 times per minute, and the amplitude is 3mm ± 0.2mm). Fix the measuring cylinder filled with loose powder on the bracket, tap 10 times, 500 times and 1250 times, and record the corresponding volumes V10, V500, and V1250 to the smallest scale. If the difference between V500 and V1250 is less than 2mL, take V1250 as the tapped volume; if the difference between V500 and V1250 is greater than 2ml, increase the number of taps until the difference between the two consecutive recorded volumes is less than 2ml. If it is verified to be feasible, a low number of taps should be selected as much as possible. Take 3 samples from the same batch, measure them in parallel, record the readings, and take the average value as the measurement result.

[0063] The tap density is calculated according to the formula ρb=m / V2, where ρb is the tap density (g / mL), m is the mass of the powder sample (g), and V2 is the tap volume of the sample (mL).

[0064] 1.2.3 Content determination

[0065] Chromatographic conditions: chromatographic column: ACE EXCEL C18-PFP (250 mm×4.6 mm, 5 μm); mobile phase methanol: 0.1% formic acid water = 25:75 (v:v); flow rate: 1.0 mL / min; UV detection wavelength: 254 nm; injection volume: 10 μL; column temperature: 30°C.

[0066] Preparation of reference solution: Accurately weigh 10 mg of scutellaria glycoside reference substance, 10 mg of gentiopicroside reference substance, and 10 mg of scutellaria glycoside reference substance, and make up to volume with methanol in a 10 mL volumetric flask.

[0067] Preparation of test solution: Take 1 g of the contents under the item of filling volume difference, accurately weigh, place in a stoppered conical flask, accurately add 50 mL of methanol, weigh the weight, ultrasonic (52 kHz, 180 W) for 30 min, cool, weigh again, make up the lost weight with methanol, shake well, filter, and take the filtrate to obtain.

[0068] Preparation of negative control solution: Prepare a negative sample of the raw material drug lacking gentiopicroside according to the prescription ratio and process, and prepare the negative control solution according to the preparation method of the test sample solution.

[0069] 1.2.3.1 Specificity test: Accurately pipette the reference solution, test solution, and negative control solution, measure according to the law, and record the chromatogram, see Figure 1Results In the chromatogram of the test solution, there was a chromatographic peak with the same retention time at the corresponding position of the chromatogram of the reference solution. The negative control solution had no interference with the determination, and the specificity was good.

[0070] 1.2.3.2 Linear relationship investigation: Take the above-mentioned swertiamarin, gentiopicroside, and swertiamarin reference stock solutions. Accurately pipette an appropriate amount of the reference solution into a 5mL volumetric flask, dilute to volume with methanol, and successively prepare 0.5mg / mL, 0.2mg / mL, 0.125mg / mL, 0.025mg / mL, 0.01275mg / mL, 0.00625mg / mL of swertiamarin, 2mg / mL, 0.6mg / mL, 0.4mg / mL, 0.04mg / mL, 0.004mg / mL, 0.001mg / mL of gentiopicroside, and 1.0mg / mL, 0.2mg / mL, 0.1mg / mL, 0.05mg / mL, 0.025mg / mL, 0.01275mg / mL of swertiamarin reference solutions. Take 10 μL of each of the above prepared reference solutions and inject them into the liquid chromatograph to measure the peak area. Draw the standard curve and obtain the linear regression equation Table 3:

[0071] Table 3 Linear regression equation

[0072]

[0073] 1.2.3.3 Precision: Accurately pipette 10 μL of the above-mentioned reference solution, repeat the injection 6 times, and measure the peak area. The RSDs of scutellariamarin, gentiopicroside, and scutellaria glycoside were 0.27%, 0.20%, and 0.13%, respectively.

[0074] 1.2.3.4 Stability: Accurately pipette 10 μL of the same test solution, inject at 0, 2, 4, 6, 8, 10, 12, and 24 hours, and measure the peak area. The results showed that the RSDs of scutellaria glycoside, gentiopicroside, and scutellaria glycoside were 1.08%, 0.95%, and 2.07%, respectively, indicating that the solution was basically stable within 24 hours.

[0075] 1.2.3.5 Repeatability: Accurately weigh 6 portions of the test sample, treat the samples according to the test sample preparation method under 1.5, and determine the peak areas of relevant components under the above-mentioned chromatographic conditions. The results showed that the RSDs of scutellariamarin, gentiopicroside, and scutellaria glycoside were 0.70%, 0.84%, and 0.82%, respectively.

[0076] 1.2.3.6 Sample recovery test: Weigh 3 portions of capsule powder accurately, and add 1:0.8, 1:1, and 1:1.2 of gentiopicroside, swertiarin, and swertiamarin standards respectively. Prepare according to the method for preparing the test solution, determine the content under the conditions, and calculate the sample recovery of each component. This shows that the sample extraction and preparation methods have good accuracy.

[0077] 1.2.4 Dissolution test

[0078] Take 1 capsule, weigh it accurately, select 900mL of 0.1mol / L hydrochloric acid solution as the dissolution medium, take 6 samples of each medium for parallel test, use the speed of 100r / min, operate according to the basket method of the 2020 edition of the Chinese Pharmacopoeia, take 5mL of samples at 5, 10, 15, 30, 45, and 60min, filter through a 0.45μm microporous membrane, and absorb the filtrate as the test solution. Determine the peak area value of each test solution according to the above chromatographic conditions and calculate the solubility.

[0079] 2. Experimental results

[0080] 2.1 Excipient and filler formulation design and results

[0081] Samples of the contents of Zangyinchen capsules were prepared according to four prescription designs. The dissolution amount and angle of repose of the four groups of samples were measured at 60 min. The results are shown in Tables 7-8.

[0082] Table 7 60min dissolution under different prescription conditions

[0083]

[0084] Table 8 Angle of repose under different prescription conditions

[0085]

[0086] The results showed that when the ratio of API to excipient filler was 2:8 and 4:6, there was no significant change in the dissolution amount and angle of repose. Therefore, the relatively better ratio of API to excipient was 4:6.

[0087] 2.2 Formulation design and results of excipients and glidants

[0088] Samples of the contents of Zangyinchen Capsules were prepared according to three different glidant prescriptions. The addition of different glidants was investigated and the repose angles of the three groups of samples were measured. The results are shown in Table 9.

[0089] Table 9 Angle of repose under different prescription conditions

[0090]

[0091] The results showed that the angle of repose was smaller when silicon dioxide and magnesium stearate were added, and the angle of repose was significantly reduced after mannitol was added. Therefore, silicon dioxide and magnesium stearate were selected as glidants.

[0092] 2.3 Final prescription design and results

[0093] Based on the results of the three formulation designs of the aforementioned glidants, the effects of different filler compositions on dissolution, bulk density, tap density, etc. were determined. The results are shown in Tables 10 to 12.

[0094] Table 10 Dissolution under different formulation conditions

[0095]

[0096] Table 11 Bulk density and tap density under different prescription conditions

[0097]

[0098] Table 12 Determination of main components under different prescription conditions

[0099]

[0100]

[0101] The results showed that after adding different fillers, more than 90% of them could be dissolved within 10 minutes. However, when mannitol was added, the repose angle was small, the fluidity was good, and the bulk density and tap density were large. Therefore, mannitol was selected as the filler.

[0102] 3. Summary

[0103] Through prescription design and optimization, the excipients finally selected were mannitol XL, colloidal silicon dioxide and magnesium stearate, with proportions of 58.2%, 2% and 1% respectively.

[0104] The final formula of Tibetan Artemisia Capsule is as follows:

[0105] Raw materials type Proportion API Tibetan Artemisia Capillaris Extract 38.8% Fillers Mannitol 58.2% Glidants Magnesium Stearate 1% Glidants Colloidal Silica 2%

[0106] In summary, the Tibetan Artemisia Capsules of the present invention are formed by mixing the contents of specific auxiliary materials in different amounts, and have a small angle of repose, good fluidity, and large bulk density and tap density. The contents are filled in the capsule shell, and the quality of the obtained capsules meets the requirements of the pharmacopoeia, and the cost is low, so the capsules are suitable for actual large-scale industrial production.

Claims

1. A Tibetan Artemisia Capsule Contents, characterized in that: It is prepared from the following raw materials in percentage by weight: Filler 55%-59%, flow aid 3%-6%, the rest is Tibetan Artemisia capillaris extract; The Tibetan Artemisia Capillaris extract is an alcohol extract of Tibetan Artemisia Capillaris.

2. The contents of the Tibetan Artemisia Capsule according to claim 1, characterized in that: It is prepared from the following raw materials in percentage by weight: Filler 58.2%, flow aid 3%, Tibetan Artemisia Capillaris extract 38.8%.

3. The contents of the Tibetan Artemisia Capsule according to claim 1 or 2, characterized in that: The filler is mannitol.

4. The contents of the Tibetan Artemisia Capsule according to claim 3 are characterized in that: The glidant is magnesium stearate and / or silicon dioxide.

5. The contents of the Tibetan Artemisia Capsule according to claim 1, characterized in that: The glidant is magnesium stearate and silicon dioxide in a mass ratio of 1:2-5.

6. The contents of the Tibetan Artemisia Capsule according to claim 1, characterized in that: The glidant is magnesium stearate and silicon dioxide in a mass ratio of 1:

2.

7. The content of the Tibetan Artemisia Capsule according to any one of claims 4 to 6, characterized in that: The silicon dioxide is colloidal silicon dioxide.

8. The contents of the Tibetan Artemisia Capsule according to claim 1, characterized in that: The Tibetan Artemisia Capillaris extract is obtained by reflux extraction of Tibetan Artemisia Capillaris with 75% ethanol, and removing ethanol and medicinal residues from the extract.

9. A Tibetan Artemisia Capsule, characterized in that: The present invention is a capsule prepared by filling a capsule shell with the content described in any one of claims 1 to 8.

10. A method for preparing the Tibetan Artemisia Capsule according to claim 9, characterized in that: It includes the following steps: Weigh the raw and auxiliary materials according to the above ratio, mix them evenly, and fill them into capsule shells to obtain the product.

Citation Information

Patent Citations

  • Method for preparing Tibetan capillary injection

    CN101084964A

  • General flavanone capsule of desmodium styracifolium and preparation method and application thereof

    CN103893246A

  • Tibetan capillary artemisia granules and preparation method thereof

    CN115887387A